VYCOR MEDICAL, INC.
VYCO · Healthcare · $2.3M mkt cap · FY2025 filings · Narrow moat ·
On the watchlist
The five investor questions
2022–2025: revenue 1222989.00 to 1863400.00, increasing; diluted EPS -0.02 to -0.01, increasing.
Median gross margin 88.6% over 10y, very stable.
Not enough years of ROIC data to score returns on capital.
Net cash position — no leverage risk.
Owner earnings trend unclear, share count growing (dilution).
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
Price vs. owner-earnings value range
- Owner earnings (normalized)
- —
- Value range / share
- —
- Conservative high estimate / share
- —
- Recent price
- $0.07
- Price vs. high estimate
- No price data
Conservative range under moat-index@2.0.0: low end 11.1×, high end capped at 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
17 years of fundamentals
The business, in plain English
VYCOR MEDICAL, INC. booked $1.9M of revenue in FY2025 in the Healthcare sector and kept 83.8% of it as gross profit — a high-margin business by that measure. After every other cost, −3.9% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $316450 (FY2010) to $1.9M (FY2025) — about 12.5% a year compounded over 15 years.
It earned −14.0% on invested capital in FY2021, with a median of −197.0% across 3 filed years.
The balance sheet carried $150000 of total debt in FY2021. Balance-Sheet Safety scores it 100/100.
The share count fell 95.4% between FY2010 and FY2025 — management has been retiring shares, which concentrates each remaining owner's claim. Capital Discipline scores it 24/100.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in VYCO’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Track record
How VYCOR MEDICAL, INC.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored VYCO on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, VYCO did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#44 of 736 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #42NOC NORTHROP GRUMMAN CORP /DE/74.4 out of 100, Narrow moatNarrow moat
- #43DXCM DEXCOM, INC.74.1 out of 100, Narrow moatNarrow moat
- #45AME AMETEK, Inc.72.8 out of 100, Narrow moatNarrow moat
- #46ENSG ENSIGN GROUP, INC72.5 out of 100, Narrow moatNarrow moat
Compare VYCO with its nearest peers →All Healthcare companies on the Index →
Common questions about VYCO
- Does VYCOR MEDICAL, INC. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores VYCOR MEDICAL, INC. (VYCO) 73.5 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 70, pricing power 100, returns on capital not measurable from the filings, balance-sheet safety 100, capital discipline 24.
- How has VYCO's Moat Score changed over time?
- The record logs 8 readings since Jul 17, 2026; the latest reads 73.5 out of 100 (narrow moat). No tier changes on record yet. (A methodology upgrade on Jul 20, 2026 re-based the score; readings across engine versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.